

09/713,425

Amendments to the Specification:

On page 1, lines 9-12, please replace the cross-reference paragraph with the following:

This is a continuation-in-part application claiming priority to non-provisional application No. 09/483,588, filed January 14, 2000, now US Patent No. 6,737,056, issued May 18, 2004, which claims priority under 35 USC § 119 to provisional application No. 60/116,023 filed January 15, 1999, the entire disclosures of which are incorporated herein by reference.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-59. (cancelled)

60. (currently amended) A polypeptide comprising a variant Fc region with increased affinity for an FcγR allotype, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 265, 267, 268, 270, 290, 298, 307, 315, 320, 331, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the polypeptide is noncovalently bound ex vivo to an FcγR allotype or an extracellular domain thereof.

61. (previously presented) The polypeptide of claim 60 wherein the FcγR allotype for which the polypeptide has increased affinity is selected from the group consisting of FcγRIIIA-Phel58, FcγRIIIA-Val158, FcγRIIA-R131 and FcγRIIA-H131.

62. (original) The polypeptide of claim 60 which displays increased binding to FcγRIIIA-Phel58.

63. (original) The polypeptide of claim 62 comprising an amino acid modification at any one or more of amino acid positions 290, 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

64.-79. (cancelled)

09/713,425

80. (currently amended) A polypeptide comprising a variant Fc region, which polypeptide comprises an amino acid substitution at any one or more of amino acid positions 290, 298, 333 or 334 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat, and wherein the polypeptide is noncovalently bound ex vivo to FcγRIIIA-Phe158 or an extracellular domain thereof.

81. (previously presented) The polypeptide of claim 80 which comprises an antibody.

82. (previously presented) The polypeptide of claim 80 wherein the variant Fc region comprises a variant human IgG Fc region.